LBS-002

N/A

Report date: 2022/08/23 20:00:44
NME

Base Information

Drug NameLBS-002
Drug Alias NameLBS002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Sydney
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLin Bioscience Inc
Active IndicationsN/A
Inactive IndicationsBrain Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A